Stabilis. Noms commerciaux. 4 mg/ml 22 C mg/ml 4 C ,6 mg/ml -20 C ,62 mg/ml -20 C mg/ml 25 C

Full text

(1)

Stabilis

Methylprednisolone sodium succinate

Noms commerciaux

Lemod

Serbie

Metilbetasone

Italie

Prednol

Turquie

Solomet

Finlande

Solu-Medrol

Afrique du sud, Autriche, Canada,

Croatie, Danemark, Finlande, France,

Italie, Norvège, Pologne, Portugal,

Tchéquie, Slovenie, Suède, Suisse

Solu-Medrone

Grande Bretagne, Irlande

Urbason

Autriche, Espagne, Italie

Stabilité des solutions

4 mg/ml

22°C

24

212

4 mg/ml

4°C

7

212

4,6 mg/ml

-20°C

365

22

4,62 mg/ml

-20°C

365

22

10 mg/ml

25°C

4

1627

10 mg/ml

5°C

21

1627

0,125 mg/ml

22°C

24

1067

0,125 mg/ml

4°C

24

1067

1 mg/ml

4°C

7

1922

10 mg/ml

23°C

2

1922

10 mg/ml

4°C

21

1922

(2)

Stabilité en mélange

0,5 & 2 mg/ml

37°C

Theophylline : 0,4 mg/ml

12

391

0,5 & 2 mg/ml

37°C

Theophylline : 4 mg/ml

24

391

2,26 mg/ml

22°C

Granisetron hydrochloride : 0,056 mg/ml

3

29

0,04 mg/ml

?

Ranitidine hydrochloride : 0,05 mg/ml

24

210

2 mg/ml

?

Ranitidine hydrochloride : 0,05 & 2 mg/ml 24

210

0,04 mg/ml

?

Ranitidine hydrochloride : 2 mg/ml

48

210

0,4 & 1,25 mg/ml

24°C

Cimetidine hydrochloride : 3 mg/ml

24

211

0,04 & 2 mg/ml

?

Ranitidine hydrochloride : 0,05 & 2 mg/ml 48

210

2,26 mg/ml

22°C

Granisetron hydrochloride : 0,15 mg/ml

3

29

0,51 mg/ml

5°C

Cytarabine : 3,85 mg/ml

Methotrexate sodium : 1,54 mg/ml

12

3275

2,4 mg/ml 20°C-25°C

Ondansetron hydrochloride : 0,16 mg/ml

24

2012

2,4 mg/ml

4°C

Ondansetron hydrochloride : 0,16 mg/ml

48

2012

1,2 mg/ml 20°C-23°C

Topotecan : 0,028 mg/ml

4

1026

Incompatibilités

Methylprednisolone sodium succinate : 5 mg/ml

Allopurinol sodium : 3 mg/ml

307

Methylprednisolone sodium succinate

Amoxicillin sodium / clavulanic acid

3545

Methylprednisolone sodium succinate : 5 mg/ml

Amsacrine : 1 mg/ml

253

Methylprednisolone sodium succinate : 5 mg/ml

Caspofungin acetate : 0.7 mg/ml

2247

Methylprednisolone sodium succinate : 20 mg/ml

Ceftolozane / tazobactam : 10 / 5 mg/ml

3828

Methylprednisolone sodium succinate : 62 mg/ml

Ciprofloxacin lactate : 2 mg/ml

288

Methylprednisolone sodium succinate : 5 mg/ml

Cisatracurium besylate : 2 & 5 mg/ml

299

Methylprednisolone sodium succinate

Daunorubicin hydrochloride

3604

Methylprednisolone sodium succinate : 20 mg/ml

Diltiazem hydrochloride : 5 mg/ml

198

Methylprednisolone sodium succinate : 2.5 mg/ml

(3)

Methylprednisolone sodium succinate : 62.5 mg/ml

Diltiazem hydrochloride : 5 mg/ml

198

Methylprednisolone sodium succinate : 5 mg/ml

Docetaxel : 0.9 mg/ml

1754

Methylprednisolone sodium succinate : 5 mg/ml

Etoposide phosphate : 5 mg/ml

1410

Methylprednisolone sodium succinate : 5 mg/ml

Filgrastim : 30 µg/ml

244

Methylprednisolone sodium succinate : 5 mg/ml

Gemcitabine hydrochloride : 38 mg/ml

1423

Methylprednisolone sodium succinate : 20 mg/ml

Isavuconazonium sulfate : 1.5 mg/ml

3829

Methylprednisolone sodium succinate : 5 mg/ml

Lansoprazole : 0.55 mg/ml

1625

Methylprednisolone sodium succinate : 3 mg/ml

Morphine hydrochloride : 20 mg/ml

1866

Methylprednisolone sodium succinate : 5 mg/ml

Paclitaxel : 1.2 mg/ml

248

Methylprednisolone sodium succinate : 5 mg/ml

Palonosetron hydrochloride : 50 µg/ml

2107

Methylprednisolone sodium succinate : 5 mg/ml

Propofol

300

Methylprednisolone sodium succinate : 63 mg/ml

Propofol

660

Methylprednisolone sodium succinate

Rocuronium bromide

3564

Methylprednisolone sodium succinate : 5 mg/ml

Sargramostim : 10 µg/ml

335

Methylprednisolone sodium succinate : 5 mg/ml

Telavancin hydrochloride : 7,5 mg/ml

3254

Methylprednisolone sodium succinate

Vancomycin hydrochloride

3385

Methylprednisolone sodium succinate : 5 mg/ml

Vinorelbine tartrate : 1 mg/ml

84

Voie d’administration

Bibliographie

Type

Source

22 Revue Sewell GJ, Palmer AJ.

The chemical and physical stability of three intravenous infusions subjected to frozen storage and microwave thawing.

(4)

29 Revue Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C.

Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. J Pharm Sci 1995 ; 84: 267-268.

84 Revue Trissel LA, Martinez JF.

Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.

Am J Hosp Pharm 1994 ; 51: 495-499. 198 Revue Gayed AA, Kheshary PR, Hinkle RL.

Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.

210 Revue Stewart JT, Warren FW, King AD.

Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.

211 Revue Strom JG, Miller SW.

Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection.

Am J Hosp Pharm 1991 ; 48: 1237-1241. 212 Revue Nahata MC, Morosco RS, Hipple TF.

Stability of diluted methylprednisolone sodium succinate injection at two temperatures. Am J Hosp Pharm 1994 ; 51: 2157-2159.

244 Revue Trissel LA, Martinez JF.

Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.

248 Revue Trissel LA, Martinez JF.

Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.

253 Revue Trissel LA, Chandler SW, Folstad JT.

Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.

288 Revue Cervenka P, Dejong DJ, Butler BL, Monzingo MD.

Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.

Hosp Pharm 1992 ; 27: 957-958,961-962. 299 Revue Trissel LA, Martinez JF, Gilbert DL.

Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.

300 Revue Trissel LA, Gilbert DL, Martinez JF.

Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.

307 Revue Trissel LA, Martinez JF.

Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.

335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.

Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.

Am J Hosp Pharm 1992 ; 49: 402-406.

391 Revue Johnson CE, Cohen IA, Michelini TJ, McMahon RE.

Compatibility of premixed theophylline and methylprednisolone sodium succinate intravenous admixtures. Am J Hosp Pharm 1987 ; 44: 1620-1624.

660 Revue Michaels MR, Stauffer GL, Haas DP.

Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.

(5)

1026 Revue Mayron D, Gennaro AR.

Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.

1067 Revue Zeidler C, Dettmering D, Schrammel W, Spieteller M.

Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.

1410 Revue Trissel LA, Martinez JF, Simmons M.

Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.

1423 Revue Trissel LA, Martinez JF, Gilbert DL.

Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.

1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.

Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.

1627 Revue Das Gupta V.

Chemical stability of methylprednisolone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes.

Int J Pharm Compound 2001 ; 5: 148-150. 1754 Revue Trissel LA, Gilbert DL, Wolkin AC.

Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.

1866 Revue Vermeire A, Remon JP.

Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone.

Int J Pharm 1998 ; 174: 157-177. 1922 Revue Trissel LA, Zhang Y.

Stability of methylprednisolone sodium succinate in autodose infusion system bags. J Am Pharm Assoc 2002 ; 42: 868-870.

2012 Revue Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M.

Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.

Am J Health-Syst Pharm 2005 ; 62: 2001-2005. 2107 Revue Trissel LA, Zhang Y, Xu QA.

Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.

Int J Pharm Compound 2006 ; 10: 234-236. 2247 Revue Chan P, Heatherly K, Kupiec T.C, Trissel L.A.

Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 2008; 12, 3: 276-278.

3254 Revue Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.

Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.

3275 Revue D’Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B

Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate Am J Health-Syst Pharm 2012 ; 69: 232-240.

3385 Revue Raverdi V, Ampe E, Hecq JD, Tulkens PM.

Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.

3545 Laboratoire Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit. Mylan SAS 2009

(6)

3564 Laboratoire Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012

3604 Laboratoire Daunorubiine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012

3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.

Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 2015

3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.

Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 2015

(7)

Dictionnaire

Antiinflammatoire

Injectable

Noms commerciaux

Stabilité des solutions

Contenant

Molécule

Concentration

Température

Conservation

Heure

Biosimilaire

Données conflictuelles

Bibliographie

Verre

Eau pour préparation injectable

A l’abri de la lumière

Heure

Jour

Polyvinyl chlorure

Chlorure de sodium 0,9%

Polypropylène

Non précisée

Polyéthylène

NaCl 0,9% ou glucose 5%

Ethylène vinyl acétate

Stabilité en mélange

Solvant

Molécule

Glucose 5%

Lumière

Aucun

Polyolefine

Non précisé

Incompatibilités

Voie d’administration

Intraveineuse

Perfusion intraveineuse

Intramusculaire

Figure

Updating...

References

Updating...

Related subjects :